SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk ...

Encouraged by initial successes with ketamine, researchers including Peter Nagele, a professor of anesthesia and psychiatry ...

Blockbuster weight loss drugs like Ozempic could leave users at a higher risk of depression and suicidal thoughts, a ...

Molecular Sciences, researchers at the University of Mississippi center found that cinnamaldehyde – a primary component of ...

Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in common that they are triggered by an excessive immune response -- which in ...

But buprenorphine’s strength as a treatment is also a weakness. Buprenorphine is an opioid. Like methadone, the tightly ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between ...

Stimulating a receptor in adipocytes enhanced energy expenditure and caused sustained weight loss in mice, offering targets ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Glucagon-like peptide 1 receptor agonists, which are found in Ozempic-like drugs, can could cause devastating symptoms in ...

A study shed light on the side effects of mental health, narrowing down those who are genetically more vulnerable.